News

ascopubs.org5d
An observational/translational study to conduct real-world evidence and develop biomarkers of fruquintinib for patients with metastatic colorectal cancer (mCRC): FruBLOOM trial ...
OrigAMI-2: A randomized, phase 3 study of amivantamab vs cetuximab, both in combination with FOLFOX or FOLFIRI, as first-line treatment in left-sided RAS/BRAF wild-type metastatic colorectal cancer.
ascopubs.org5d
Trial in progress: First-in-human study of ATX-559, an oral inhibitor of DHX9, in patients with advanced or metastatic solid tumors, and molecularly defined cancers.
Phase 1 first-in-human clinical trial of AG01, a recombinant monoclonal antibody to progranulin/glycoprotein 88 (PGRN/GP88), to determine the safety, tolerability ...